Patent details

EP2593463 Title: FORMULATIONS OF RIFAXIMIN AND USES THEREOF

Basic Information

Publication number:
EP2593463
PCT Application Number:
US2011043769
Type:
European Patent Granted for LU
Legal Status:
In force
Application number:
EP118074186
PCT Publication Number:
WO2012009388
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
FORMULATIONS OF RIFAXIMIN AND USES THEREOF
French Title of Invention:
FORMULATIONS DE RIFAXIMINE ET UTILISATIONS CORRESPONDANTES
German Title of Invention:
FORMULIERUNGEN VON RIFAXIMIN UND ANWENDUNGEN DAVON
SPC Number:

Dates

Filing date:
12/07/2011
Grant date:
06/05/2020
EP Publication Date:
22/05/2013
PCT Publication Date:
19/01/2012
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
06/05/2020
EP B1 Publication Date:
06/05/2020
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
Expiration date:
12/07/2031
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
29/04/2020
 
 

Name:
Salix Pharmaceuticals, Inc.
Address:
400 Somerset Corporate Boulevard, Bridgewater, NJ 08807, United States (US)

Agent

Name:
NOVAGRAAF BREVETS
From:
29/07/2020
Address:
BÂTIMENT O2, 2 RUE SARAH BERNHARDT CS90017, 92665, ASNIÈRES-SUR-SEINE cedex, France (FR)
To:

Inventor

1

Name:
TENG, Jing
Address:
United States (US)

2

Name:
KABIR, Mohammed, A.
Address:
United States (US)

3

Name:
SELBO, Jon
Address:
United States (US)

4

Name:
GOLDEN, Pam
Address:
United States (US)

Priority

1

Priority Number:
363609 P
Priority Date:
12/07/2010
Priority Country:
United States (US)

2

Priority Number:
419056 P
Priority Date:
02/12/2010
Priority Country:
United States (US)

Classification

IPC classification:
A61K 9/10; A61K 9/14; A61K 9/16; A61K 9/48; A61K 31/437; C07D 498/22;

Publication

European Patent Bulletin

1

Issue number:
202019
Publication date:
06/05/2020
Description:
Grant (B1)

2

Issue number:
202024
Publication date:
10/06/2020
Description:
Application number/publication number of the divisional application (Art. 76) changed

Annual Fees

Annual Fee Due Date:
31/07/2025
Annual Fee Number:
15
Annual Fee Amount:
213 Euro
Expected Payer:
Last Annual Fee Payment Date:
26/06/2024
Last Annual Fee Paid Number:
14
Last Annual Fee Paid Amount:
198 Euro
Payer:
CPA GLOBAL THE IP PLATFORM
Filing date Document type Number of pages
29/07/2020 Outgoing Correspondence 1
29/07/2020 Power Of Attorney 2